Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arrow Therapeutics

This article was originally published in Start Up

Executive Summary

The genomics approach of Arrow Therapeutics provides selective antimicrobial targets

You may also be interested in...



Where Are They Now?

In a new occasional series, START-UP will select companies it profiled in the past to find out what went according to plan, and what didn't. This month, we revisit four anti-infectives discovery companies first profiled in 2000 and draw out some lessons, both from their successes and from their failures, for those starting out today.

Where Are They Now?

In a new occasional series, START-UP will select companies it profiled in the past to find out what went according to plan, and what didn't. This month, we revisit four anti-infectives discovery companies first profiled in 2000 and draw out some lessons, both from their successes and from their failures, for those starting out today.

Arrow: Focus and Flexibility

In October 2003, infectious diseases start-up Arrow Therapeutics' £21 million funding round from four new international VCs and five existing backers topped the ranks of UK biotech fundraisings. The round shows that investors value a broad pipeline, plus well-connected management able to balance focus with opportunism, more than a product in the clinic or a sexy new technology.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090172

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel